Generalized pustular psoriasis of pregnancy (GPPP), characterized by widespread sterile pustules and erythematous patches with systemic symptoms such as fever, is a rare form of pustular psoriasis. GPPP typically occurs in the third trimester of pregnancy and can be triggered by various factors such as infections, hypocalcemia, and drugs including -butyl-scopolammonium bromide. We report a rare case of new-onset GPPP in a 33-year-old multigravida female at 17 weeks' gestation, which occurred earlier than usual, after taking hydroxychloroquine for 3 weeks to treat systemic lupus erythematosus. She stopped her medications and was treated with systemic corticosteroid, but without improvement. Her medication was changed to systemic cyclosporine; her skin lesions improved, which completely resolved after delivery. This is the first case of GPPP developed following hydroxychloroquine use for systemic lupus erythematosus, which occurred earlier than usual and completely resolved after delivery. This case demonstrates that hydroxychloroquine can induce GPPP before the third trimester of pregnancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608382PMC
http://dx.doi.org/10.5021/ad.21.062DOI Listing

Publication Analysis

Top Keywords

pustular psoriasis
12
generalized pustular
8
psoriasis pregnancy
8
third trimester
8
trimester pregnancy
8
occurred earlier
8
earlier usual
8
systemic lupus
8
lupus erythematosus
8
completely resolved
8

Similar Publications

Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.

Ital J Dermatol Venerol

January 2025

Department of Dermatology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan (ROC) -

Risankizumab (Skyrizi, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies.

View Article and Find Full Text PDF

Background: Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular psoriasis variant refractory to many conventional treatments. The eruption typically occurs after local trauma or infection; other etiologies include neural, inflammatory, and genetic causes. Herein we reported a single case of a 64-year-old patient with ACH that was successfully treated with spesolimab for 19 weeks.

View Article and Find Full Text PDF

Background: Generalized pustular psoriasis (GPP) is a rare, chronic, often unpredictable, severe multisystemic autoinflammatory skin disease from which patients can experience flares, episodes of widespread eruptions of painful, sterile pustules often accompanied by systemic symptoms. The impact of GPP flares and underlying GPP severity on the healthcare resource utilization (HCRU) is not well characterized.

Objective: To quantify HCRU among US GPP patients by flare status and underlying severity.

View Article and Find Full Text PDF

Successful treatment of severe acrodermatitis continua of hallopeau with Bimekizumab: A case report.

SAGE Open Med Case Rep

January 2025

Faculty of Medicine, Division of Dermatology, University of Ottawa, Ottawa, ON, Canada.

Acrodermatitis continua of Hallopeau is a rare form of pustular psoriasis affecting the acral fingers and toes, characterized by recurrent eruptions of sterile pustules that lead to significant pain and potentially irreversible destruction of the nail apparatus. Symptoms are often refractory to topical and systemic therapies for psoriasis. This case report presents a healthy 23-year-old female with severe acrodermatitis continua of Hallopeau, destructing all 10 fingernails.

View Article and Find Full Text PDF

Background: Generalised pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease. A previous Delphi panel established areas of consensus on GPP, although patient perspectives were not included, and aspects of treatment goals remain unclear.

Objectives: To identify and achieve consensus on refined, specific treatment goals for GPP treatment via a Delphi panel with patient participation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!